Summary: Angiotensin II receptor antagonists (ARBs) belong to the major groups of antihypertensive drugs used in the treatment of hypertension, both as monotherapy and in combination. The subject of the review is one of the younger representatives of this group of drugs – olmesartan – which was registered by the FDA in 2002. Many clinical studies using this drug have been carried out in Polish centers. Due to the high antihypertensive efficacy and beneficial effect on organ complications and progression of atherosclerosis, this drug is a valuable complement to the available antihypertensive drugs on our market.